Skip to main content
Journal of Ophthalmic Inflammation and Infection
Fig. 1 | Journal of Ophthalmic Inflammation and Infection

Fig. 1

From: Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy

Fig. 1

Clinical findings of bilateral blepharitis and conjunctivitis after dupilumab. Bilateral blepharitis, bilateral conjunctival hyperemia, and papillary hyperplasia were observed at 10 weeks after dupilumab administration for AD (a). These findings disappeared at 30 weeks by treatment with 0.1% cyclosporine eye drops and 0.1% methylprednisolone ointment (b)

Back to article page